Entasis Therapeutics Holdings Inc. (ETTX): Price and Financial Metrics
ETTX Price/Volume Stats
| Current price | $2.19 | 52-week high | $3.88 |
| Prev. close | $2.20 | 52-week low | $1.40 |
| Day low | $2.19 | Volume | 68,800 |
| Day high | $2.20 | Avg. volume | 239,104 |
| 50-day MA | $2.06 | Dividend yield | N/A |
| 200-day MA | $2.23 | Market Cap | 104.80M |
ETTX Stock Price Chart Interactive Chart >
Entasis Therapeutics Holdings Inc. (ETTX) Company Bio
Entasis Therapeutics Inc. discovers and develops antibacterials to fight diseases caused by multidrug-resistant bacteria. It offers ETX2514, a broad-spectrum and potent inhibitor of class A, C, and D beta-lactamases that has activity against Acinetobacter baumannii, a gram-negative bacterium that causes severe infections, which are associated with high mortality; ETX0914, a novel oral antibiotic for the treatment of uncomplicated gonorrhea; and a drug discovery platform that focuses on developing novel antibacterials targeting serious gram-negative infections, such as pneumonia, infections of the blood, urinary tract infections, and infections following surgery. Entasis Therapeutics Inc. has strategic development collaboration with Zai Lab Limited. The company was founded in 2015 and is based in Waltham, Massachusetts. Entasis Therapeutics Inc. operates as a subsidiary of AstraZeneca PLC.
ETTX Price Returns
| 1-mo | N/A |
| 3-mo | N/A |
| 6-mo | N/A |
| 1-year | N/A |
| 3-year | -16.09% |
| 5-year | -54.78% |
| YTD | N/A |
| 2023 | N/A |
| 2022 | 0.00% |
| 2021 | -11.34% |
| 2020 | -50.30% |
| 2019 | 22.11% |
Loading social stream, please wait...